Single-cell spatial landscapes of the lung tumour immune microenvironment.
Sorin M, Rezanejad M, Karimi E, Fiset B, Desharnais L, Perus LJM, Milette S, Yu MW, Maritan SM, Doré S, Pichette É, Enlow W, Gagné A, Wei Y, Orain M, Manem VSK, Rayes R, Siegel PM, Camilleri-Broët S, Fiset PO, Desmeules P, Spicer JD, Quail DF, Joubert P, Walsh LA. · 2023
Read Single-cell spatial landscapes of the lung tumour immune microenvironment. by Sorin M, Rezanejad M, Karimi E, Fiset B, Desharnais L, Perus LJM, Milette S, Yu MW, Maritan SM, Doré S, Pichette É, Enlow W, Gagné A, Wei Y, Orain M, Manem VSK, Rayes R, Siegel PM, Camilleri-Broët S, Fiset PO, Desmeules P, Spicer JD, Quail DF, Joubert P, Walsh LA. (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc9931585.txt.
Introduction
Sorin and co-authors map single-cell spatial landscapes of the lung tumor immune setting. Tumor subtypes are often classed by tissue type alone. The spatial layout of cell types inside those groups stays poorly known. The team applied imaging mass cytometry to lung adenocarcinoma samples.
Samples came from 416 patients across five histological patterns. The team resolved more than 1.6 million cells for spatial analysis. Immune lineages and activation states showed distinct links to outcomes, including survival. A deep learning model predicted post-surgery progression from a single 1-mm2 tumor core. It did so with high accuracy. The dataset is shared as a resource for lung cancer research. It shows how AI can read tumor layout for care.
Catalog record
| CREATOR | Sorin M, Rezanejad M, Karimi E, Fiset B, Desharnais L, Perus LJM, Milette S, Yu MW, Maritan SM, Doré S, Pichette É, Enlow W, Gagné A, Wei Y, Orain M, Manem VSK, Rayes R, Siegel PM, Camilleri-Broët S, Fiset PO, Desmeules P, Spicer JD, Quail DF, Joubert P, Walsh LA. |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 59 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Single-cell spatial landscapes of the lung tumour immune microenvironment By Mark Sorin, Morteza Rezanejad, Elham Karimi, Benoit Fiset, Lysanne Desharnais, Lucas J. M. Perus, Simon Milette, Miranda W. Yu, Sarah M. Maritan, Samuel Doré, Émilie Pichette, William Enlow Published in: Nature DOI: 10.1038/s41586-022-05672-3 ABSTRACT Single-cell technologies have revealed the complexity of the tumour immune microenvironment with unparalleled resolution1–9. Most clinical strategies rely on histopathological stratification of tumour subtypes, yet the spatial context of single-cell phenotypes within these stratified subgroups is poorly understood. Here we apply imaging mass cytometry to characterize the tumour and immunological landscape of samples from 416 patients with lung adenocarcinoma across five histological patterns. We resolve more than 1.6 million cells, enabling spatial analysis of immune lineages and activation states with distinct clinical correlates, including survival. Using deep learning, we can predict with high accuracy those patients who will progress after surgery using a single 1-mm2 tumour core, which could be informative for clinical management following surgical resection. Our dataset represents a valuable resource for the non-small cell lung cancer research community and exemplifies the utility of spatial resolution within single-cell analyses. This study also highlights how artificial intelligence can improve our understanding of microenvironmental features that underlie cancer progression and may influence future clinical practice. MAIN Lung cancer remains the leading cause of cancer-related death, accounting for greater than 20% of all cancer mortalities10. Lung adenocarcinoma (LUAD), a type of non-small cell lung cancer (NSCLC), is the most common subtype and is characterized by distinct cellular and molecular features11. The tumour immune microenvironment (TIME) is a major source of LUAD heterogeneity and influences both disease progression and response to therapy1,3,5. The positioning of immune cells within tumours is known to dictate their function12–14; therefore, understanding the spatial landscape of the lung TIME would provide mechanistic insights into disease progression, reveal novel therapeutic vulnerabilities and unveil biomarkers of response to existing treatments. Here, using highly multiplexed imaging mass cytometry (IMC), we interrogated spatially resolved features of the TIME that are associated with clinical outcomes in patients with LUAD. Using a deep neural network model, we demonstrated that various clinical outcomes, such as progression, can be predicted using features that an artificial intelligence-based system can extract from raw IMC images. The ability to identify patients who will progress with a high degree of certainty could guide future post-surgical management. LUAD TUMOUR IMMUNE MICROENVIRONMENT To spatially characterize the cellular landscape of the lung TIME, we applied IMC to samples from 416 patients with LUAD (Fig. 1a, Extended Data Fig. 1a and Supplementary Table 1). We optimized a 35-plex antibody panel to identify cancer cells, stromal cells, and innate and adaptive immune lineages with diverse functional substates (Extended Data Figs. 1b–d and 2–4 and Supplementary Table 2). In total, we detected 1,644,178 cells and used a supervised lineage assignment approach to classify 14 distinct immune cell populations, along with tumour cells and endothelial cells using canonical lineage markers (Fig. 1b–f and Extended Data Figs. 1c and 5a).Fig. 1IMC defines the spatial landscape of LUAD.a, Schematic depicting IMC acquisition of multiplexed images from 416 patients with LUAD, single-cell phenotyping, survival and machine learning prediction of clinical outcomes. CyTOF, cytometry by time of flight. Images were created with BioRender. b, Average expression of lineage markers across cell types in the LUAD tissue using the panel of isotope-conjugated antibodies. Cl Mo, classical monocyte; Int Mo, intermediate monocyte; Mac, macrophage; NK, natural killer; non-Cl Mo, non-classical monocyte; Tc, cytotoxic T cell; TH, helper T cell. c, Waterfall plot depicting the distribution of 16 stromal and immune cell types across histological subgroups. d, Representative images of antibody staining and corresponding single-cell segmented images across histological subgroups. Scale bars, 100 μm. e,f, Prevalence of 17 cell types, including 14 immune cell types, across 416 patients with LUAD as a proportion of total cells (e) and immune cells (f). g–i, Prevalence of all immune (g), myeloid (h) and lymphoid (i) cells across lepidic (n = 40), papillary (n = 33), acinar (n = 190), micropapillary (n = 35) and solid (n = 118) architectural patterns as a proportion of total cells. Comparison between lepidic and solid (immune cells): **P = 0.0013. Comparison between papillary and solid (immune cells): **P = 0.0039. Comparison between lepidic and solid (myeloid cells): ****P ≤ 0.0001. Comparison between papillary and solid (myeloid cells): *P = 0.0474. Comparison between acinar and solid (myeloid cells): **P = 0.0072. Data shown as mean ± s.e.m. (e–i). One-way ANOVA with Tukey multiple comparison test was used for statistical analysis (g–i). Consistent with previous work15, high-grade solid tumours had the greatest immune infiltrate (44.6%) compared with micropapillary, acinar, papillary and lepidic architectures (37.0%, 39.7%, 32.8% and 32.7% respectively; Fig. 1g). This was driven by shifts within the myeloid compartment, as there were no significant differences in the average frequency of total lymphoid cells across histological patterns (Fig. 1h,i). In particular, macrophages were the most frequent cell population within the lung TIME, representing 12.3% of total cells (Fig. 1e) and 34.1% of immune cells (Fig. 1f), consistent with their critical role in the NSCLC niche16. We found the highest enrichment of CD163+ macrophages (putative ‘M2-like’ or protumorigenic) in solid tumours, which are one of the most aggressive architectures (Extended Data Fig. 5b, Supplementary Table 3, Supplementary Fig. 1, xii). The prevalence of CD163+ macrophages was strongly correlated with FOXP3+ immunoregulatory T cells (Treg cells) in the solid pattern (Extended Data Fig. 5c, box 1). This relationship was much less pronounced in low-grade lepidic and papillary architectures, which had a strong correlation between CD163+ macrophages and cytotoxic CD8+ T cells (Extended Data Fig. 5c, box 2). These associations suggest a potential interplay between macrophage and T cell populations in the TIME across LUAD patterns. Of note, solid tumours were also enriched for additional myeloid components, including neutrophils, non-classical monocytes and intermediate monocytes (Supplementary Fig. 1, ii, xiv and xv). Similarly to macrophages, these myeloid populations all exhibit diverse functional states in NSCLC biology4 and exemplify the complex heterogeneity that exists in the lung TIME. LUAD MULTICELLULAR SPATIAL INTERACTIONS We next assessed the relationship between immune populations and clinical or pathological variables by interrogating the frequency of individual cell types as a percentage of total cells within each image (Fig. 2a,b, Supplementary Tables 1 and 4 and Supplementary Fig. 1). Each image was cross-referenced with clinical data from patients, including sex, age, body mass index (BMI), smoking status, stage, progression, survival and histological subtype. Although we discovered established survival associations for several cell types17,18, most were driven by an enrichment in specific clinical or pathological groups. For example, although mast cells were associated with prolonged survival, they were overrepresented in non-smokers, early-stage patients and those with lepidic tumours (Fig. 2b, box 1)—all clinical variables associated with good outcomes. Similarly, CD163+ macrophages, non-classical monocytes and intermediate monocytes were enriched in solid tumours, which have poor outcomes (Fig. 2b, box 2). By contrast, B cell frequency was most significantly associated with better overall survival, independent of any confounding clinical or pathological variables (Fig. 2b, box 3).Fig. 2Variability in single-cell distributions across clinical variables and in cell–cell interaction profiles across histological patterns in LUAD.a, Prevalence of Tc cells (CD8+ T cells) across sex